Patents by Inventor Linda Masat

Linda Masat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Shoelace knot retainer
    Patent number: 10716363
    Abstract: The shoelace knot retainer is configured for use with a shoelace. The shoelace knot retainer holds the shoelace in position after the shoelace has been tightened on the shoe. The shoelace knot retainer comprises a pedestal, a stanchion, and a sleeve. The pedestal is intermediate structure that transfers the load of the shoelace knot retainer to the surface of the shoe. The stanchion forms an anchor point around which the shoelace is wound. The shoelace is wound around the stanchion during the tightening process. The sleeve is an elastomeric structure. The stanchion and the shoelace insert into the sleeve such that the sleeve compresses around the shoelace thereby holding the shoelace in position. The stanchion is further formed with an accommodation that secures the tips of the shoelace to the stanchion.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: July 21, 2020
    Inventor: Linda Masat
  • Antagonist antibodies against EphB3
    Patent number: 9541004
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: January 10, 2017
    Assignees: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: Linda Masat, Jeff Hsu
  • Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof
    Patent number: 9206252
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: December 8, 2015
    Assignee: XOMA (US) LLC
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • ANTAGONIST ANTIBODIES AGAINST EPHB3
    Publication number: 20150183872
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 2, 2015
    Inventors: Linda Masat, Jeff Hsu
  • PRLR-SPECIFIC ANTIBODY AND USES THEREOF
    Publication number: 20150175705
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: March 3, 2015
    Publication date: June 25, 2015
    Inventors: Jason Damiano, Mohammad Luqman, Linda Masat, Amer Mirza, Genevieve Nonet, Daniel Bedinger
  • PRLR-specific antibody and uses thereof
    Patent number: 9005614
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 14, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • EPHB3-specific antibody and uses thereof
    Patent number: 9006398
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 14, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jeff Hsu, Linda Masat, Judy Abraham, Masahisa Handa, Siew Schleyer
  • Antagonist antibodies against EphB3
    Patent number: 8961969
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: February 24, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Linda Masat, Jeff Hsu
  • EPHB3-SPECIFIC ANTIBODY AND USES THEREOF
    Publication number: 20140148584
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: October 16, 2013
    Publication date: May 29, 2014
    Applicants: XOMA Technology Ltd., Novartis AG
    Inventors: Jeff Hsu, Linda Masat, Judy Abraham, Masahisa Handa, Siew Schleyer
  • EPHB3-specific antibody and uses thereof
    Patent number: 8586716
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: November 19, 2013
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jeff Hsu, Linda Masat, Judy Abraham, Masahisa Handa, Siew Schleyer
  • Method of treating inflammatory eye disease with IL-1? binding antibodies
    Patent number: 8377442
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: February 19, 2013
    Assignee: Xoma Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
  • Antagonist antibodies against EPHB3
    Patent number: 8377439
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: February 19, 2013
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Ssucheng Jeff Hsu, Linda Masat
  • Human antibodies specific for gastrin materials and methods
    Patent number: 8278421
    Abstract: The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: October 2, 2012
    Assignee: Xoma Techolology Ltd.
    Inventors: Linda Masat, Marina Roell
  • Fully human anti-VEGF antibodies and methods of using
    Patent number: 8216571
    Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: July 10, 2012
    Assignee: Schering Corporation
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang, Toshihiko Takeuchi, Seema Kantak, Chin-Yi Huang
  • IL-1BETA BINDING ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20120014967
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Application
    Filed: May 17, 2011
    Publication date: January 19, 2012
    Applicant: XOMA TECHNOLOGY LTD.
    Inventors: Linda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
  • Method of treating an IL-1 related coronary condition
    Patent number: 7988968
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: August 2, 2011
    Assignee: Xoma Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • PRLR-Specific Antibody and Uses Thereof
    Publication number: 20110150760
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Application
    Filed: November 22, 2010
    Publication date: June 23, 2011
    Applicants: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: JASON DAMIANO, MOHAMMAD LUQMAN, DANIEL BEDINGER, LINDA MASAT, AMER MIRZA, GENEVIEVE NONET
  • IL-1? binding antibodies and fragments thereof
    Patent number: 7943121
    Abstract: An IL-1? binding antibody or IL-1? binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1? binding polypeptide. IL-1? binding antibodies or IL-1? binding fragments thereof are provided which have desirable affinity and potency.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 17, 2011
    Assignee: XOMA Technology Ltd.
    Inventors: Linda Masat, Mary Haak-Frendscho, Arnold H. Horwitz, Gang Chen, Marina Roell
  • FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
    Publication number: 20110097340
    Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Application
    Filed: October 20, 2008
    Publication date: April 28, 2011
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang, Toshihiko Takeuchi, Seema Kantak, Chin-Yi Huang's
  • FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
    Publication number: 20110076279
    Abstract: Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Application
    Filed: October 22, 2007
    Publication date: March 31, 2011
    Applicants: SCHERING CORPORATION, XOMA TECHNOLOGY LTD.
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang